Interactions of Ergot Compounds with Dopamine Receptors and Endocrine Functions

  • E. Flückiger
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 18)


Ergot compounds may affect endocrine systems through stimulatory and inhibitory dopamine receptors at the hypothalamic and the pituitary level. In most cases, with the exception of the prolactin and the melanotropin cell receptors, the characterization of the dopamine receptor involved is not yet satisfactory. Comparing in vivo or in vitro dopaminomimetic activities of ergot compounds produces a multiplicity of profiles of actions without a clear pattern.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adams, E. F., Ashby, M.J., Brown, S. M., White, M. C., Mashiter, K.: Bromocriptine suppresses ACTH secretion from human pituitary tumour cells in culture by a dopaminergic mechanism. Clin. Endocrinol. 15, 479–484 (1981).CrossRefGoogle Scholar
  2. Agnati, L., Fuxe, K., Löfström, A., Hökfelt, T: Dopaminergic drugs and ovulation: Studies on PMS-induced ovulation and changes in median eminence DA and NE turnover in immature female rats. In: Advances in Biochemical Psychopharmacology (Costa, E., Gessa, G. L., eds.), p. 159. New York: Raven Press. 1977.Google Scholar
  3. Bansal, S., Woolf, P. D., Fischer, J.A., Caro, J. F.: Dopamine does not affect parathyroid function in man. J. Clin. Endocrinol. Metab. 54, 651–652 (1982).CrossRefPubMedGoogle Scholar
  4. Bethea, C. L., Ramsdell, J. S.,Jaffe, R. B., Wildson, C. B., Weiner, R.I.: Characterization of the dopaminergic regulation of human prolactin secreting cells cultured on extracellular matrix. J. Clin. Endocrinol. Metab. 54, 893–902 (1982).Google Scholar
  5. Bevilacqua, M., Vago, T, Malacco, E., Norblato, G.: Characterization of dopaminergic receptors in calf adrenal glomerulosa cells. Abstract, Symp. on Dopamine Receptor Agonists, Stockholm, April 20–23, 1982.Google Scholar
  6. Bisset, G. W.: The milk ejection reflex. In: Neurohypophysial Hormones and Similar Peptides (Berde, B., ed.) (Handbook of Exp. Pharmacology, Vol. XXIII), p. 475. Berlin-Heidelberg-New York: Springer. 1968.CrossRefGoogle Scholar
  7. Blum, J. W., Kunz, P., Fischer, J. A., Binswanger, U., Lichtensteiger, W, da Prada, M.: Parathyroid hormone response to dopamine in cattle. Am. J. Physiol. 239, 255–264 (1980).Google Scholar
  8. Bression, D., Brandi, A. M., Nousbaum, A., LeDafniet, M., Racadot, J., Peilion, F.: Evidence of dopamine receptors in human growth hormone (GH)-secreting adenomas with concomitant study of dopamine inhibition of GH secretion in a perifused system. J. Clin. Endocrinol. Metab. 55, 589–593 (1982).CrossRefPubMedGoogle Scholar
  9. Bridges, T.E., Hillhouse, E. W., Jones, M. T: The effect of dopamine on neurohypophysial hormone release in vivo and from the rat neural lobe and hypothalamus in vitro. J. Physiol. 260, 647–666 (1976).CrossRefPubMedCentralPubMedGoogle Scholar
  10. Brown, E. M., Caroll, R.J., Aurbach, G. D.: Dopaminergic stimulation of cyclic AMP accumulation and parathyroid hormone release from dispersed bovine parathyroid cells. Proc. Natl. Acad. Sci. USA 74, 4210–4213 (1977).CrossRefPubMedCentralPubMedGoogle Scholar
  11. Calabro, M.A., MacLeod, R.M.: Binding of dopamine to bovine anterior pituitary gland membranes. Neuroendocrinology 25, 32–46 (1976).CrossRefGoogle Scholar
  12. Camanni, F., Massara, F., Belforte, L., Molinatti, G. M.: Changes in plasma growth hormone levels in normal and acromegalic subjects following administration of 2-bromo-a-ergokryptine. J. Clin. Endocrinol. Metab. 40, 363–366 (1975).CrossRefPubMedGoogle Scholar
  13. Carey, R. M., Thorner, M. O.: Dopaminergic inhibition of metoclopramide induced aldosterone secretion in man: dissociation of responses to dopamine and bromocriptine. J. Clin. Invest. 66, 10–15 (1980).CrossRefPubMedCentralPubMedGoogle Scholar
  14. Carey, R. M., Thorner, M. O., Ortt, E.: Dopaminergic inhibition of metoclopramide-induced aldosterone secretion in man. J. Clin. Invest. 66, 10–18 (1980).CrossRefPubMedCentralPubMedGoogle Scholar
  15. Carey, R. M., Van Loon, G. R.: Bromocriptine does not inhibit the aldosterone response to sodium depletion. J. Clin. Endocrinol. Metab. 55, 162–165 (1982).CrossRefPubMedGoogle Scholar
  16. Caron, G. M., Beaulieu, M., Raymond, V., Gagne, B., Drouin, J., Lefkowitz, J., Labrie, F.: Dopaminergic receptors in the anterior pituitary gland. J. Biol. Chem. 253, 2244–2253 (1978).PubMedGoogle Scholar
  17. Clarke, G., Lincoln, D. W, Merrick, L.P.: Dopaminergic control of oxytocin release in lactating rats. J. Endocr. 83, 409–420 (1979).CrossRefPubMedGoogle Scholar
  18. Connell, J. M. C.: Bromocriptine for inappropriate thyrotropin secretion. Ann. Intern. Med. 96, 251–252 (1982).CrossRefPubMedGoogle Scholar
  19. Cote, T. E., Grewe, C. W, Kebabian, J. W: Stimulation of a D-2 dopamine receptor in the intermediate lobe of the rat pituitary gland decreases the responsiveness of the ß-adrenoceptor: Biochemical mechanism. Endocrinology 108, 420–426 (1981).CrossRefPubMedGoogle Scholar
  20. Cronin, M.J.: The role and direct measurement of the dopamine receptor(s) in the anterior pituitary. In: Neuroendocrine Perspectives, Vol.1 (Müller, E.E., MacLeod, R.M., eds.), p. 169. Amsterdam: Elsevier Biomedical Press. 1982.Google Scholar
  21. Cronin, M.J.: Some calcium and lysosome antagonists inhibit 3H-spiperone binding to the porcine anterior pituitary. Life Sci. 30, 1385–1389 (1982).CrossRefPubMedGoogle Scholar
  22. Cronin, M.J., Cheung, C. Y, Wilson, C. B., Jaffe, R. B., Weiner, R. I.: [3H]-spiperone binding to human anterior pituitaries and pituitary adenomas secreting prolactin, growth hormone, and adrenocorticotropic hormone. J. Clin. Endocrinol. Metab. 50, 387–391 (1980).CrossRefPubMedGoogle Scholar
  23. Delitala, G., Yeo, T, Grossman, A., Hathway, N. R., Besser, G. M.: A comparison of the effects of four ergot derivatives on prolactin secretion by dispersed rat pituitary cells. J. Endocr. 87, 95–103 (1980).CrossRefPubMedGoogle Scholar
  24. del Pozo, E., Lancranjan, I.: Clinical use of drugs modifying the release of anterior pituitary hormones. In: Frontiers in Neuroendocrinology (Ganong, W F., Martini, L., eds.), Vol. 5, p. 207. New York: Raven Press. 1978.Google Scholar
  25. del Pozo, E., Darragh, A., Lancranjan, 1., Ebeling, D., Burmeister, P., Bühler, F., Marbach, P., Braun, P.: Effect of bromocriptine on the endocrine system and fetal development. Clin. Endocrinol. 6 (Suppl.), 47–55 (1977).Google Scholar
  26. Denef, C., Baes, M.: ß-Adrenergic stimulation of prolactin release from superfused pituitary aggregates. Endocrinology 111, 356–358 (1982).CrossRefPubMedGoogle Scholar
  27. El-Denshary, E. E., Ismail, N. A., Gagesman, E., Sehling, J., Täl edal, L-B.: Bromocriptine and insulin secretion. Bioscience Reports 2, 115–116 (1982).CrossRefPubMedGoogle Scholar
  28. Evans, W. S., Rogol, A. D., MacLeod, R.M., Thorner, M. O.: Dopaminergic mechanism and luteinizing hormone secretion. I. Acute administration of the dopamine agonist bromocriptine does not inhibit luteinizing hormone release in hyperprolactinemic women. J. Clin. Endocrinol. 50, 103–107 (1980).PubMedGoogle Scholar
  29. Evans, W. S., Cronin, M.J., Thorner, M. O.: Hypogonadism in hyperprolactinemia: Proposed mechanism. In: Frontiers in Neuroendocrinology (Ganong, W. F., Martini, L., eds.), Vol. 7, p. 77. New York: Raven Press. 1982.Google Scholar
  30. Flückiger, E.: Lactation inhibition by ergot drugs. In: Physiology of Mammary Glands (Yokoyama, A., Mizouno, H., Nagasawa, H., eds.), p.71. Tokyo: Japan Scientific Societies Press/Baltimore: University Park Press. 1978.Google Scholar
  31. Flückiger, E.: Ergots and endocrine functions. In: Ergot Compounds and Brain Function. Neuroendocrine and Neuropsychiatric Aspects (Goldstein, M., Calne, D. B., Liebermann, A., Thorner, M. O., eds.), p. 155. New York: Raven Press. 1980.Google Scholar
  32. Flückiger, E.: Inhibitors of prolactin secretion. In: Advances in Pharmacology and Therapeutics II, Vol. 1: CNS Pharmacology, Neuropeptides (Yoshida, H., Hagihara, Y., Ebashi, S., eds.), pp. 129. Oxford: Pergamon Press. 1982.Google Scholar
  33. Flückiger, E., del Pozo, E.: Influence on the endocrine system. In: Ergot Alkaloids and Related Compounds (Berde, B., Schild, H. U., eds.) (Handbook of Experimental Pharmacology, Vol.49), p. 615. Berlin-HeidelbergNew York: Springer. 1978.CrossRefGoogle Scholar
  34. Flückiger, E., Vigouret, J.-M., Wagner, H.-R.: Ergot compounds and prolactin secretion. In: Progress in Prolactin Physiology and Pathology (Robyn, C., Harter, M., eds.), p. 383. Amsterdam: Elsevier/North-Holland Biomedical Press. 1978.Google Scholar
  35. Flückiger, E., Vigouret, J.-M.: Drugs, dopamine and pituitary secretion. In: Medicinal Chemistry VI, Proc. 6th Internat. Symp. Med. Chem., Brighton, 1978 (Simkins, M. A., ed.), p. 469. Oxford: Cotswold Press. 1979.Google Scholar
  36. Flückiger, E., Briner, U., Bürki, H.R., Marbach, P., Wagner, H-R., Doepfner, W.: Two novel prolactin release-inhibiting 8a-amino-ergolines. Experientia 35, 1677–1678 (1979).CrossRefPubMedGoogle Scholar
  37. Flückiger, E., del Pozo, E.: Ergot derivatives and pituitary hormones. In: Neuroactive Drugs in Endocrinology (Müller, E.E., ed.), p. 169. Amsterdam: Elsevier/North-Holland Biomedical Press. 1980.Google Scholar
  38. Flückiger, E., Briner, U., Kovacs, E., Markstein, R., Stürmer, E., Vigouret, J.-M., Wagner, H.-R.: Prolactin secretion stimulation by an ergopeptine. Experientia 37, 669 (1981).Google Scholar
  39. Flückiger, E., Briner, U., Enz, A., Markstein, R., Vigouret, J.-M.: Dopaminergic ergot compounds: An overview. In: Lisuride and Other Dopamine Agonists: Basic Mechanisms and Endocrine and Neurological Effects (Calne, D. B., Horowski, R., McDonald, R., Wuttke, W., eds.), p. 1–9. New York: Raven Press. 1982.Google Scholar
  40. Flückiger, E., del Pozo, E., von Werder, K.: Prolactin, Physiology, Pharmacology and Clinical Findings. (Monographs on Endocrinology, Vol. 23.) BerlinHeidelberg-New York: Springer. 1982 b.Google Scholar
  41. Flückiger, E., Markstein, R.: Receptor pharmacology of ergot compounds. In: Human Prolactin (Tolis, G., ed). New York: Raven Press. 1982 (in press).Google Scholar
  42. Foord, S. M., Peters, Scanlon, M. F., Bees Smith, B., Hall, R.: Dopaminergic control of TSH secretion in isolated rat pituitary cells. FEBS Letters 121, 257–259 (1980).Google Scholar
  43. Grossman, A., Yeo, T, Delitala, G., Hathway, N. R., Besser, G. M.: Two new dopamine agonists that are long acting in vivo but short acting in vitro. Clin. Endocrinol. 13, 595–599 (1980).CrossRefGoogle Scholar
  44. Hauth, H.: Chemical aspects of ergot derivatives with central dopaminergic activity. In: Dopaminergic Ergot Derivatives and Motor Function (Fuze, K., Caine, D.B., eds.), p. 23. Oxford: Pergamon Press. 1979.CrossRefGoogle Scholar
  45. Kebabian, J. W., Calne, D.B.: Multiple receptors for dopamine. Nature 277, 93–96 (1979).CrossRefPubMedGoogle Scholar
  46. Kerdelhue, B., Weisman, A. S., Weiner, R. I.: A dopaminergic binding site in the high speed supernatant of steer anterior pituitary homogenates. Endocrinology 109, 307–309 (1981).CrossRefPubMedGoogle Scholar
  47. Köbberling, J., Darragh, A., del Pozo, E.: Chronic dopamine receptor stimulation using bromocriptine: Failure to modify thyroid function. Clin. Endocrinol. 11, 367–370 (1979).CrossRefGoogle Scholar
  48. Krulich, L.: Neurotransmitter control of thyrotropin secretion. Neuroendocrinology 35, 139–147 (1982).CrossRefPubMedGoogle Scholar
  49. Labrie, F., Borgeat, P., Drouin,J., Lagace, L., Giguere, V., Raymond, V., Godbout, M., Massicotte,J., Ferland, Barden, N., Beaulieu, M., Cote,J., Lepine,J., Meunier, H., Veileux, R.: The role of cyclic nucleotides in the control of anterior pituitary gland activity. In: Cyclic Nucleotides II (Kebabian, J. W., Nathanson,J.A., eds.), p. 525. Berlin-Heidelberg-New York: Springer. 1982.CrossRefGoogle Scholar
  50. Lachelin, G. C. L., Leblanc, H., Yen, S. S. C.: The inhibitory effect of dopamine agonists on LH release in women. J. Clin. Endocrinol. Metab. 44, 728–732 (1977).CrossRefPubMedGoogle Scholar
  51. Lal, S., de la Vega, C. E., Sourkes, T. L., Friesen, H. G.: Effect of apomorphine on human growth hormone secretion. Lancet II, 661 (1972).Google Scholar
  52. Lauer, C. G., Braley, L.A., Menachery, A.I., Williams, G. H.: Metoclopramide inhibits aldosterone biosynthesis in vitro. Endocrinology 111, 238–243 (1982).CrossRefPubMedGoogle Scholar
  53. Lawton, N. F., Evans, A.J., Weller, R. O.: Dopaminergic inhibition of growth hormone and prolactin release during continuous in vitro perifusion of normal and adenomatous human pituitary. J. Neurol. Sci. 49, 229–239 (1981).CrossRefPubMedGoogle Scholar
  54. Leblanc, H., Lachelin, G. C. L., Abu-Fadil, S., Yen, S. S. C.: Effects of dopamine infusion on pituitary hormone secretion in humans. J. Clin. Endocrinol. Metab. 43, 668–674 (1976).CrossRefPubMedGoogle Scholar
  55. Lincoln, D. W, Paisley, A. C.: Neuroendocrine control of milk ejection. J. Reprod. Fert. 65, 571–586 (1982).CrossRefGoogle Scholar
  56. Liuzzi, A., Chiodini, P. G., Botalla, L., Cremascoli, G., Silvestrini, F.: Inhibitory effect of L-DOPA on GH release in acromegalic patients. J. Clin. Endocrinol. Metab. 35, 941–943 (1972).CrossRefPubMedGoogle Scholar
  57. Liuzzi, A., Chiodini, P. G., Botalla, L., Cremascoli, G., Müller, E. E.: Decreased plasma growth hormone (GH) levels in acromegalics following CB 154 administration. J. Clin. Endocrinol. Metab. 38, 910–912 (1974).CrossRefPubMedGoogle Scholar
  58. Liuzzi, A., Panerai, A. E., Chiodini, P. G., Secchi, C., Cocchi, D., Botalla, L., Silvestrini, F., Müller, E. E.: Neuroendocrine control of growth hormone secretion: Experimental and clinical studies. In: Growth Hormone and Related Peptides (Peelle, A., Müller, E. E., eds.), p. 236. Amsterdam: Excerpta Medica. 1976.Google Scholar
  59. MacLeod, R. M.: Regulation of prolactin secretion. In: Frontiers in Neuroendocrinology, Vol. IV (Martini, L., Ganong, W. F., eds.), p. 169. New York: Raven Press. 1976.Google Scholar
  60. Marko, M., Flückiger, E.: Inhibition of spontaneous and induced ovulation in rats by non-steroidal agents. Experientia 30, 1174–1176 (1974).CrossRefPubMedGoogle Scholar
  61. Marko, M., Flückiger, E.: Role of serotonin in the regulation of ovulation. Evidence for pharmacological studies. Neuroendocrinology 30, 228–231 (1980).CrossRefPubMedGoogle Scholar
  62. Markovitz, S., Goodyer, C. G., Guyda, H., Gardiner, R.J., Hardy, J.: Comparative study of human fetal, normal adult, and somatotropic adenoma pituitary function in tissue culture. J. Clin. Endocrinol. Metab. 54, 6–16 (1982).CrossRefGoogle Scholar
  63. Markstein, R.: Neuroendocrine effects of some ergot derivatives. A basis for their antiparkinson actions. J. Neural Transm. 51, 39–59 (1981).CrossRefPubMedGoogle Scholar
  64. Martin, W. H., Rogol, A.D., Kaiser, D.L., Thorner, M. O.: Dopaminergic mechanism and luteinizing hormone (LH) secretion. II. Differential effects of dopamine and bromocriptine on LH release in normal women. J. Clin. Endocrinol. Metab. 52, 650–656 (1981).CrossRefPubMedGoogle Scholar
  65. Mashiter, K., Adams, E., Beard, M., Holley, A.: Bromocriptine inhibits prolactin and growth hormone release by human pituitary tumours in culture. Lancet 11, 197–198 (1977).CrossRefGoogle Scholar
  66. Massara, F., Camanni, F., Belforte, L., Molinatti, G. M.: Dopamine-induced inhibition of prolactin and growth hormone secretion in acromegaly. Lancet 1, 485 (1976).CrossRefPubMedGoogle Scholar
  67. Massara, F., Camanni, F., Belforte, L., Molinatti, G. M.: Dopamine and inhibition of prolactin and growth hormone secretion. Lancet 1, 913 (1976).CrossRefPubMedGoogle Scholar
  68. Maurer, R. A.: Dopaminergic inhibition of prolactin synthesis and prolactin messenger RNA accumulation in cultured pituitary cells. J. Biol. Chem. 255, 8092–8097 (1980).PubMedGoogle Scholar
  69. Maurer, R.A. (1981): Transcriptional regulation of the prolactin gene by ergocryptine and cyclic AMP. Nature 294, 94–97 (1981).CrossRefPubMedGoogle Scholar
  70. Maurer, R. A.: Adenosine 3’, 5’-monophosphate derivatives increase prolactin synthesis and prolactin messenger ribonucleic acid levels in ergocryptine-treated pituitary cells. Endocrinology 110, 1957–1963 (1982).CrossRefPubMedGoogle Scholar
  71. Moos, F., Richard, Ph.: Effects of dopaminergic antagonists and agonists on oxytocin release induced by various stimuli. Neuroendocrinology 28, 138–144 (1979).CrossRefPubMedGoogle Scholar
  72. Munemura, M., Cote, T. E., Tsuruta, K., Eskay, R. L., Kebabian, J. W.: The dopamine receptor in the intermediate lobe of the rat pituitary gland: Pharmacological characterization. Endocrinology 107, 1676–1683 (1980 a).Google Scholar
  73. Munemura, M., Eskay, R.L., Kebabian, J. W.: Release of a-melanocytestimulating hormone from dispersed cells of the intermediate lobe of the rat pituitary gland. Involvement of catecholamines and adenosine 3’, 5’- monophosphate. Endocrinology 106, 1795–1803 (1980 b).Google Scholar
  74. Nansel, D. D., Gudelsky, G.A., Reymond, M.J., Neaves, W.B., Porter, J. C.: A possible role for lysosomes in the inhibitory action of dopamine on prolactin release. Endocrinology 108, 896–902 (1981).CrossRefPubMedGoogle Scholar
  75. Penny, R.J., Thody, A.J.: Preliminary studies on the control of a-melanocytestimulating hormone secretion in the rat. J. Endocr. 69, 2–3 (1976).Google Scholar
  76. Penny, R.J., Tilders, F.J. H., Thody, A.J.: The role of the dopaminergic tuberohypophyseal neurones in the maintenance of “basal” melanocyte-stimulating hormone levels in the rat. J. Endocrinol. 80, 58–59 (1979).Google Scholar
  77. Perryman, R. L., Rogol, A. D., Kaiser, D. L., MacLeod, R. M., Thorner, M. O.: Pergolide mesylate: Its effects on circulating anterior pituitary hormones in man. J. Clin. Endocrinol. Metab. 53, 772–778 (1981).CrossRefPubMedGoogle Scholar
  78. Russel, J. A., Harrison, D.J., McNeilly, A. S.: Bromocriptine and a-ergocryptine do not inhibit oxytocin secretion in the lactating rat. J. Endocr. 89, 91–98 (1981).CrossRefGoogle Scholar
  79. Sarkar, D.K., Fink, G.: Gonadotropin-releasing hormone surge: possible modulation through postsynaptic a-adrenoceptors and two pharmacologically distinct dopamine receptors. Endocrinology 108, 862–867 (1981).CrossRefPubMedGoogle Scholar
  80. Scatton, B.: Effect of dopamine agonists and neuroleptic agents on striatal acetylcholine transmission in the rat: Evidence against dopamine receptor multiplicity. J. Pharmacol. Exp. Therap. 220, 197–202 (1982).Google Scholar
  81. Scholtysik, G., Müller-Schweinitzer, E.: Evidence of presynaptic dopamine receptors in sympathetic heart nerves of cats. In: Modulation of Neurochemical Transmission (Vizi, E. S., ed.), p.189. London: Pergamon Press/ Budapest: Akadémiai Kiad 6. 1980.Google Scholar
  82. Seybold, V. S., Miller, J. W., Lewis, P. R.: Investigation of a dopaminergic mechanism for regulating oxytocin release. J. Pharmacol. Exp. Ther. 207, 605–610 (1978).PubMedGoogle Scholar
  83. Thorner, M. O., Ryan, S. M., Wass, J. A. H., Jones, A., Bouloux, P., Williams, S., Besser, G. M.: Effect of the dopamine agonist lergotrile mesylate, on circulating anterior pituitary hormones in man. J. Clin. Endocrinol. Metab. 47, 372 (1978).CrossRefPubMedGoogle Scholar
  84. Thorner, M. O., Flückiger, E., Calne, D. B.: Bromocriptine, A Clinical and Pharmacological Review. New York: Raven Press. 1980.Google Scholar
  85. Tolis, G., Pinter, E.J., Friesen, H. G.: The acute effect of 2-bromo-a-ergokryptine (CB 154) on anterior pituitary hormones and free fatty acids in man. J. Clin. Pharmacol. 12, 281–283 (1975).Google Scholar
  86. Tsuruta, K., Frey, E.A., Grewe, C. W, Cote, T. E., Eskay, R.L., Kebabian, J. W.: Evidence that LY-141865 specifically stimulates the D-2 dopamine receptor. Nature 292, 463–465 (1981).Google Scholar
  87. Verde, G., Oppizzi, G., Colussi, G., Cremascoli, G., Botala, L., Müller, E. E., Silvestrini, F., Chiodini, P. G., Liuzzi, A.: Effect of dopamine infusion on plasma levels of growth hormone in normal subjects and in acromegalic patients. Clin. Endocrinol. 5, 419–423 (1976).CrossRefGoogle Scholar
  88. Vesely, D. L.: Bromocriptine enhances guanylate cyclase activity. Endocrinology 109, 1284–1286 (1981).CrossRefPubMedGoogle Scholar
  89. Vigouret, J. M., Bürki, H. R., Jaton, A. L., Züger, P. E., Loew, D. M.: Neurochemical and neuropharmacological investigations with four ergot derivatives. Pharmacology 16 (Suppl. 1), 156–173 (1978).CrossRefPubMedGoogle Scholar
  90. Wass, J. A. H., Clemmons, D. R., Underwood, L. E., Barrow, I., Besser, G. N., Van Wyk, J.J.: Changes in circulating somatomedin-C levels in bromocriptine-treated acromegaly. Clinical Endocrinol. (in press).Google Scholar
  91. Weiner, R. I., Ganong, W. F.: Role of brain monoamines and histamine in regulation of anterior pituitary secretion. Physiol. Revs. 58, 905–976 (1978).Google Scholar
  92. Woolf, P.D.: Resumption of prolactin secretion after dopaminergic inhibition: differential effects of dopamine and its agonists. Am. J. Physiol. 240, 700–704 (1981).Google Scholar
  93. Yeo, T., Thorner, M. O.,Jones, A., Lowry, P.J., Besser, G. M.: The effects of dopamine, bromocriptine, lergotrile and metoclopramide on prolactin release from continuously perfused columns of isolated rat pituitary cells. Clin. Endocrinol. 10, 123–130 (1979).CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1983

Authors and Affiliations

  • E. Flückiger
    • 1
  1. 1.Preclinical Research, Pharma DivisionSandoz Ltd.BasleSwitzerland

Personalised recommendations